Ardena Adds CFO and CCO as CDMO Scales Complex Molecule Push

Ardena is signaling a deliberate shift toward structured international scale, appointing Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer as the Ghent-based CDMO positions its nanomedicine, drug conjugate, and bioanalytical capabilities for broader market reach. For biotech sponsors evaluating contract development partners in complex modalities, the leadership build-out reflects an organization moving from capability investment into commercial execution.

Ash brings over 20 years of pharmaceutical finance experience, including CFO roles at Essential Pharma, PTC Therapeutics, and Shire. He is a Fellow of the Institute of Chartered Accountants in England and Wales. At Ardena, he will oversee financial strategy and international expansion, and will work alongside the Chief Information Officer to advance the company's digitization roadmap. Zijlstra joins from Adragos, with prior experience at Lonza, and will lead business development and marketing across Ardena's drug development portfolio spanning complex molecules, nanotechnology, drug conjugates, and bioanalysis.

The appointments follow what CEO Jeremie Trochu described as a significant 15-month transformation period that included US expansion, divestment of Swedish operations, and continued investment in bioanalytical services, nanomedicines, and digital infrastructure. The strategic pivot toward a leaner, more internationally focused organization is now being backed by commercial and financial leadership with direct CDMO and specialty pharma credentials.

Zijlstra noted Ardena's existing reputation among biotech innovators as a foundation for building stronger brand recognition, particularly given the company's recent US market entry. Ash cited the company's scientific differentiation as a basis for scalable expansion. Both appointments reflect a pattern seen across mid-tier CDMOs: operational maturation followed by deliberate investment in the commercial and financial functions needed to compete for larger, longer-term development contracts in complex therapeutic categories.